Wednesday, July 8, 2026

Patent intelligence · US

US 10064961

Method for producing a liquid pharmaceutical preparation

granted A61KA61K49/108A61K9/08
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 60
Patent details — US 10064961

Quick answer

US 10064961 (Method for producing a liquid pharmaceutical preparation) is held by SANOCHEMIA PHARMAZEUTIKA AG. Status: granted. Granted Sep 4, 2018. Expires Aug 30, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K49/108, A61K9/08

More from SANOCHEMIA PHARMAZEUTIKA AG

Related pharmaceutical patents in our USPTO index.

  1. US 12310943

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Expires May 22, 2045

    granted
  2. US 12297182

    Compositions comprising an urolithin compound

    Amazentis SA · Expires May 8, 2045

    granted
  3. US 12226455

    Medical composition for treating cardiac wasting and cachexia

    RELAXERA PHARMAZEUTISCHE GMBH & CO. KG · Expires Feb 13, 2045

    granted
  4. US 12220424

    Compositions comprising nicotinamide riboside and a urolithin

    Amazentis SA · Expires Feb 6, 2045

    granted
  5. US 12109190

    Urolithins as immune response enhancers

    Amazentis SA · Expires Oct 3, 2044

    granted
  6. US 12036205

    Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

    Amazentis SA · Expires Jul 11, 2044

    granted
  7. US 12030863

    Prodrugs of urolithins and uses thereof

    Amazentis SA · Expires Jul 4, 2044

    granted
  8. US 11969408

    Method for improving mitophagy in subjects

    Amazentis SA · Expires Apr 25, 2044

    granted

Frequently asked questions

What is US patent 10064961?

US 10064961 (Method for producing a liquid pharmaceutical preparation) is held by SANOCHEMIA PHARMAZEUTIKA AG. Status: granted. Granted Sep 4, 2018. Expires Aug 30, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10064961?

SANOCHEMIA PHARMAZEUTIKA AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.

When does US 10064961 expire?

Our index shows an expiration date of Aug 30, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.